+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Johnson & Johnson (JNJ) - Financial and Strategic SWOT Analysis Review

Johnson & Johnson (JNJ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Johnson & Johnson (J&J) is a healthcare company engaged in the research, development, manufacture, and sale of innovative medicines and medical technologies. The company conducts business through its operating companies. It provides pharmaceutical products for therapy areas related to immune disorders, cancer, neurological disorders, infectious, cardiovascular, and metabolic diseases; and medical devices for use in cardiovascular, orthopedic, neurovascular care, general surgery, and vision care fields. The company offers its products to retailers, wholesalers, healthcare professionals, and hospitals. It operates manufacturing units in the US, Europe, Asia-Pacific, Africa, Western Hemisphere (excluding the US), and Latin America. J&J is headquartered in New Brunswick, New Jersey, the US.

Johnson & Johnson Key Recent Developments

  • Apr 30, 2026: Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
  • Apr 30, 2026: Johnson & Johnson Discontinues Investigational CAR-T Programs in Large B-Cell Lymphoma
  • Apr 29, 2026: Johnson & Johnson to Present More Than 20 Cancer Studies at ASCO 2026
  • Apr 24, 2026: AABB Announces Participating Organizations in 2026 Biotherapies Pavilion

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Johnson & Johnson - Key Facts
  • Johnson & Johnson - Key Employees
  • Johnson & Johnson - Key Employee Biographies
  • Johnson & Johnson - Major Products and Services
  • Johnson & Johnson - History
  • Johnson & Johnson - Company Statement
  • Johnson & Johnson - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Johnson & Johnson - Business Description
  • Business Segment: Innovative Medicine
  • Overview
  • Performance
  • Key Stats
  • Business Segment: MedTech
  • Overview
  • Performance
  • Key Stats
  • Geographical Segment: Asia-Pacific, Africa
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: United States
  • Performance
  • Geographical Segment: Western Hemisphere excluding U.S.
  • Performance
  • R&D Overview
  • Johnson & Johnson - Corporate Strategy
  • Johnson & Johnson - SWOT Analysis
  • SWOT Analysis - Overview
  • Johnson & Johnson - Strengths
  • Johnson & Johnson - Weaknesses
  • Johnson & Johnson - Opportunities
  • Johnson & Johnson - Threats
  • Johnson & Johnson - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Johnson & Johnson, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 30, 2026: Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
  • Apr 30, 2026: Johnson & Johnson Discontinues Investigational CAR-T Programs in Large B-Cell Lymphoma
  • Apr 29, 2026: Johnson & Johnson to Present More Than 20 Cancer Studies at ASCO 2026
  • Apr 24, 2026: AABB Announces Participating Organizations in 2026 Biotherapies Pavilion
  • Apr 22, 2026: Johnson & Johnson Receives CE Mark for ETHICON 4000 Stapler
  • Apr 16, 2026: J&J Reports 12-Month Results for Varipulse PFA Platform in AFib Treatment
  • Apr 15, 2026: J&J sets the tone for Q1 earnings with strong oncology growth
  • Apr 15, 2026: Cancer Dependency Map Consortium launches Phase 3 to accelerate next-generation therapeutics
  • Apr 08, 2026: J&J advances PFA portfolio with Varipulse Pro launch in Europe
  • Mar 28, 2026: SPRAVATO (Esketamine Nasal Spray) Shows Effectiveness and Durability for Treatment-Resistant Depression in Real-World Study
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Johnson & Johnson, Key Facts
  • Johnson & Johnson, Key Employees
  • Johnson & Johnson, Key Employee Biographies
  • Johnson & Johnson, Major Products and Services
  • Johnson & Johnson, History
  • Johnson & Johnson, Subsidiaries
  • Johnson & Johnson, Key Competitors
  • Johnson & Johnson, Ratios based on current share price
  • Johnson & Johnson, Annual Ratios
  • Johnson & Johnson, Interim Ratios
  • Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Johnson & Johnson, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Johnson & Johnson, Performance Chart (2021-2025)
  • Johnson & Johnson, Ratio Charts
  • Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Johnson & Johnson, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • L'Oreal SA
  • Cardiovascular Systems Inc
  • Boston Scientific Corp
  • Kyntra Bio Inc
  • GSK plc
  • CR Bard Inc
  • Stryker Corp
  • Kimberly-Clark Corp
  • CONMED Corp
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Sanofi
  • Novartis AG
  • Abbott Laboratories
  • The Hain Celestial Group Inc
  • Takeda Pharmaceutical Co Ltd
  • Keenova Therapeutics plc
  • Immunomedics Inc